PDCD1 and head and neck squamous cell carcinoma: Zandberg et al. reported that in an animal model of HNSCC, disease control rate (DCR) and survival were altered in mice with intra-tumoral hypoxia, rendering them resistant to anti-PD-1 immunotherapy [128].